by
Gene and cell therapies targeting disorders of the central nervous system (CNS) have garnered immense attention in recent years as a promising approach for effective treatment of neurological diseases. Gene and cell therapies involve altering specific genes to correct the genetic defect or replacing damaged cells with healthy cells. These therapies aim to treat diseases like Alzheimer’s, Parkinson’s, spinal cord injury and stroke by halting disease progression or restoring normal functioning.
The global Gene and Cell Therapies Targeting CNS Disorders Market is estimated to be valued at US$ 8.2 Bn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Emerging pipeline of novel therapies is driving the Gene and Cell Therapies Targeting CNS Disorders Market. Over the past few years, there has been a significant rise in research activities focusing on development of advanced gene and cell therapies for treatment of neurological disorders. Numerous cell-based and gene-based therapies are currently under clinical trials, with some new therapies expected to receive regulatory approvals in the coming years. For instance, AVXS-101, an investigational gene therapy for spinal muscular atrophy developed by AveXis Inc., received FDA approval in 2019. Growing research funding for development of innovative CNS therapies will further spur advances in this promising area.
SWOT Analysis
Strength: Gene and cell therapies for CNS disorders have potential to cure or manage CNS disorders more effectively than conventional therapies. They offer targeted treatment approaches.
Weakness: High costs associated with development and manufacturing of advanced gene and cell therapies. Long-term safety and efficacy data is still limited for many therapies.
Opportunity: Large patient population for CNS disorders provide significant commercial opportunities. Growing research and funding in neuroscience is expected to fast track the development of new therapies.
Threats: Stringent regulatory approvals pose delays in marketing approvals. Intense competition from existing and emerging therapies can affect market uptake.
Key Takeaways
Global Gene And Cell Therapies Targeting CNS Disorders Market Size is expected to witness high growth over the forecast period of 2023 to 2030. North America currently dominates the market driven by presence of major players, high healthcare spending, and growing clinical research. The dominance of North America region is followed by Europe and Asia Pacific regions.
Key players operating in the gene and cell therapies targeting CNS disorders market are Sophion Bioscience A/S, Nanion Technologies GmbH, NeoBiosystems, Inc., Multi Channel Systems MCS GmbH, Fluxion Biosciences, Molecular Devices, LLC, Scitech Korea Inc., and HEKA Elektronik GmbH. These key players are focusing on developing novel and more effective gene and cell therapies through increased R&D investments and clinical trials.
The North America region is expected to maintain its dominance in the global market during the forecast period. This can be attributed to the presence of major market players, higher adoption of advanced therapies, and growing research activities supported by public and private funding. Asia Pacific region is projected to witness fastest growth rate owing to rising healthcare expenditure, increasing patient population, and growing investments by market players looking to tap emerging markets.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
